Three biotech stocks were among the market's best-performing companies last week. Two of them are highly speculative, clinical-stage biotech stocks that surged on optimism about drugs in their pipelines. The third is commercial stage big-cap biotech stock that is racking up profit thanks to a fast-growing cancer drug.

It's anyone's guess whether these three biotech stocks will continue their winning ways in the months and years to come, but I've prepared a slideshow below that highlights what you need to know about PTC Therapeutics (NASDAQ:PTCT), Tesaro (NASDAQ: TSRO), and Pharmacyclics (NASDAQ: PCYC) and why each of them have recently surged by 25% or more. 

 

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis -- even one of our own -- helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.